First test of new drug targeting a key cancer driver
NCT ID NCT04111458
Summary
This is an early safety study for adults with advanced solid tumors that have a specific genetic change called a KRAS mutation, which makes cancer grow faster. The main goals are to find the highest safe dose of a new drug, BI 1701963, and to see if it can shrink tumors when given alone or combined with an existing drug, trametinib. Participants take daily pills for as long as they benefit and can tolerate the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS, KRAS MUTATION; SOS1 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Erasmus Medisch Centrum-ROTTERDAM-50697
Rotterdam, 3015 GD, Netherlands
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
Sarah Cannon Research Institute-Nashville-48456
Nashville, Tennessee, 37203, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Universitair Medisch Centrum Utrecht
Utrecht, 3584 CX, Netherlands
-
Universitätsklinikum Frankfurt
Frankfurt am Main, 60590, Germany
-
Universitätsklinikum Köln (AöR)
Cologne, 50937, Germany
Conditions
Explore the condition pages connected to this study.